Healthcare is moving out of the doctors surgery and into consumers own hands. Ageing populations, greater awareness of preventative medicine and a rising desire to remain healthier for longer are encouraging people to treat everyday ailments earlier and more proactively. At the same time, stretched hospital systems, improved products, e-commerce and increasingly sophisticated consumer brands are making self-care easier and more accessible than ever.

Step forward Venture Life Group , which has just completed perhaps the most important transformation in its 16-year history.

Here FY26 revenues came in at £50.0m for the 17 months to May 2026, up an impressive 16% LFL, split 14.8% volume vs 1.2% price. Better still, its Power Brands climbed 17% to £46.7m (93% of group), underpinned by innovation (19 new product launches), higher marketing spend (9.4% sales vs 6.1% LY) and a 156% jump in online to £12.8m (25% of group).

Indeed after selling its CDMO operations together with UltraDEX and Dentyl, Venture Life has emerged as a capital-light consumer healthcare platform focused on womens intimate health, hormonal health, energy management and ear-care. Anchored by £11.5m of net cash, despite investing £17.1m ($23m) on its transformational (up to $28m) FemiClear/CUROXEN acquisition in June.

Which will provide #VLG with not only an established sales team and relationships with Walmart, Walgreens, CVS and Target. But also turnover of approx $14m this year (vs $11m) and infrastructure to cross-pollinate existing brands Balance Activ, Health&Her, Lift and Earol into the worlds largest consumer healthcare market.

Elsewhere FY’26 EBITDA leapt 27% to £7.9m, albeit margins fell to 15.7% (23.2% LY) as #VLG invested in growth and temporarily carried an under-utilised cost base following the disposals. CEO Jerry Randall commenting: the group has “extraordinary growth prospects” and is targeting “revenues of £300m within the next 5 years alongside an adjusted EBITDA margin of 25%”.

Looking ahead Cavendish are forecasting 12M FY27 turnover, adjusted EBITDA and EPS of £54.7m, £11.6m and 6.9p respectively. Thus putting the stock at 68p on attractive multiples of 6.5x EV/EBITDA and 9.9x PER. Cavendish have a 150p/share target price vs my 112p fair value.

Finally as a normal part of succession planning, long time CEO & founder Jerry Randall is set to hand over the reins to CFO Daniel Wells in Dec'26.